Protecting Adolescents Against HPV: International Vaccination Strategies and Public Health Implications

Year 2026, Volume: 2 Issue: 1, 43 - 51, 28.01.2026

Darya Mırdamad , Bahar Kural

Abstract

Human papillomavirus (HPV) is the most important factor in the development of oropharyngeal, anogenital malignant and premalignant warts and cervix cancer in women. Transmission can occur through trauma to the skin or mucosa and with sexual intercourse. HPV infections can be prevented by vaccination and are included in vaccination programs in most countries as primary protection in adolescents. The countries that started HPV vaccination at the earliest in the world were the United States of America (USA), Switzerland, France and Monaco in 2006. Turkmenistan has the highest vaccination rate, which started the vaccination program in 2016. In this analysis Eswatini have the highest rates in cervix cancers and need to start vaccinations . Studies for adolescent health programs are continuing to initiate adolescent vaccination in Türkiye. In this review, the administration rates of HPV vaccines and the changes in HPV-related cancer rates by country in the world are examined.

Keywords

Human Papilluma Virus , Vaccination , Countries

References

• Al-Awadhi, R., Chehadeh, W., Jaragh, M., Al-Shaheen, A., Sharma, P., & Kapila, K. (2013). Distribution of human papillomavirus among women with abnormal cervical cytology in Kuwait. Diagnostic Cytopathology, 41(2). https://doi.org/10.1002/dc.21778
• Alene, T., Atnafu, A., Mekonnen, Z. A., & Minyihun, A. (2020). Acceptance of human papillomavirus vaccination and associated factors among parents of daughters in gondar town, northwest Ethiopia. Cancer Management and Research, 12. https://doi.org/10.2147/CMAR.S275038
• Arbyn, M., Simoens, C., Van Damme, P., Scharpantgen, A., Meijer, C. J. L. M., & Beutels, P. (2010). Introduction of human papillomavirus vaccination in Belgium, Luxembourg and The Netherlands. Gynecologic and Obstetric Investigation, 70(4). https://doi.org/10.1159/000314010
• Athanasiou, A., Bowden, S., Paraskevaidi, M., Fotopoulou, C., Martin-Hirsch, P., Paraskevaidis, E., & Kyrgiou, M. (2020). HPV vaccination and cancer prevention. In Best Practice and Research: Clinical Obstetrics and Gynaecology (Vol. 65). https://doi.org/10.1016/j.bpobgyn.2020.02.009
• Audisio, R. A., Icardi, G., Isidori, A. M., Liverani, C. A., Lombardi, A., Mariani, L., Mennini, F. S., Mitchell, D. A., Peracino, A., Pecorelli, S., Rezza, G., Signorelli, C., Rosati, G. V., & Zuccotti, G. V. (2016). Public health value of universal HPV vaccination. In Critical Reviews in Oncology/Hematology (Vol. 97). https://doi.org/10.1016/j.critrevonc.2015.07.015
• Blakely, T., Kvizhinadze, G., Karvonen, T., Pearson, A. L., Smith, M., & Wilson, N. (2014). Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand. Vaccine, 32(22). https://doi.org/10.1016/j.vaccine.2014.02.071
• Boiron, L., Joura, E., Largeron, N., Prager, B., & Uhart, M. (2016). Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria. BMC Infectious Diseases, 16(1). https://doi.org/10.1186/s12879-016-1483-5
• Brotherton, J. M. L., Winch, K. L., Bicknell, L., Chappell, G., & Saville, M. (2017). HPV vaccine coverage is increasing in Australia. Medical Journal of Australia, 206(6). https://doi.org/10.5694/MJA16.00958
• Carlton, J. G., Marembo, J., Manangazira, P., Rupfutse, M., Shearley, A., Makwabarara, E., Hidle, A., & Loharikar, A. (2022). Nationwide introduction of HPV vaccine in Zimbabwe 2018–2019: Experiences with multiple cohort vaccination delivery. PLOS Global Public Health, 2(4). https://doi.org/10.1371/journal.pgph.0000101
• Centers for Disease Control and Prevention. (2023). HPV vaccine information for clinicians. U.S. Department of Health & Human Services. https://www.cdc.gov/hpv/clinicians/index.html
• Chung, M., York, B. R., & Michaud, D. S. (2019). Oral Health and Cancer. In Current Oral Health Reports (Vol. 6, Issue 2). https://doi.org/10.1007/s40496-019-0213-7
• Clark, S. J., Cowan, A. E., Filipp, S. L., Fisher, A. M., & Stokley, S. (2016). Parent HPV vaccine perspectives and the likelihood of HPV vaccination of adolescent males. Human Vaccines and Immunotherapeutics, 12(1). https://doi.org/10.1080/21645515.2015.1073426
• De Groot, A. S., Tounkara, K., Rochas, M., Beseme, S., Yekta, S., Diallo, F. S., Tracy, J. K., Teguete, I., & Koita, O. A. (2017). Knowledge, attitudes, practices and willingness to vaccinate in preparation for the introduction of HPV vaccines in Bamako, Mali. PLoS ONE, 12(2). https://doi.org/10.1371/journal.pone.0171631
• Dorji, Tandin, Tshomo, U., Phuntsho, S., Tamang, T. D., Tshokey, T., Baussano, I., Franceschi, S., & Clifford, G. (2015). Introduction of a National HPV vaccination program into Bhutan. Vaccine, 33(31). https://doi.org/10.1016/j.vaccine.2015.05.078
• Dorji, Thinley, Tshomo, U., Gyamtsho, S., Tamang, S. T., Wangmo, S., & Pongpirul, K. (2022). Gender-neutral HPV elimination, cervical cancer screening, and treatment: Experience from Bhutan. In International Journal of Gynecology and Obstetrics (Vol. 156, Issue 3). https://doi.org/10.1002/ijgo.13728
• Fagot, J. P., Boutrelle, A., Ricordeau, P., Weill, A., & Allemand, H. (2011). HPV vaccination in France: Uptake, costs and issues for the National Health Insurance. Vaccine, 29(19). https://doi.org/10.1016/j.vaccine.2011.02.064
• Fisher, W. A., Laniado, H., Shoval, H., Hakim, M., & Bornstein, J. (2013). Barriers to Human Papillomavirus Vaccine Acceptability in Israel. In Vaccine (Vol. 31, Issue SUPPL.8). https://doi.org/10.1016/j.vaccine.2013.06.107
• Gordis, L. (2014). Prevention and control of disease (Chap. 8). In Epidemiology (6th ed.). Elsevier
• Garland, S. M., Skinner, S. R., & Brotherton, J. M. L. (2011). Adolescent and young adult HPV vaccination in Australia: Achievements and challenges. In Preventive Medicine (Vol. 53, Issue SUPPL. 1). https://doi.org/10.1016/j.ypmed.2011.08.015
• Ginindza, T. G., Forestier, M., & Almonte, M. (2022). Cervical cancer screening by visual inspection and HPV testing in Eswatini. Preventive Medicine, 161. https://doi.org/10.1016/j.ypmed.2022.107144
• Gomes, J. M., Silva, B. M., de Sousa Santos, E. F., Kelly, P. J., de Souza Costa, A., Takiuti, A. D., de Abreu, L. C., Júnior, J. M. S., Baracat, E. C., Cristina, I., & Sorpreso, E. (2020). Human Papillomavirus (HPV) and the quadrivalent HPV vaccine among Brazilian adolescents and parents: Factors associated with and divergences in knowledge and acceptance. PLoS ONE, 15(11 November). https://doi.org/10.1371/journal.pone.0241674
• Gultekin, M., Karaca, M. Z., Kucukyildiz, I., Dundar, S., Keskinkilic, B., & Turkyilmaz, M. (2019). Mega Hpv laboratories for cervical cancer control: Challenges and recommendations from a case study of Turkey. Papillomavirus Research, 7. https://doi.org/10.1016/j.pvr.2019.03.002
• Hamkar, R., Shoja, Z., Ghavami, N., Heydari, N., Farahmand, M., & Jalilvand, S. (2018). Type-Specific Human Papillomavirus Prevalence in Iranian Women with Normal Cervical Cytology: The Impact of Current HPV Vaccines. Intervirology, 60(4). https://doi.org/10.1159/000485898
• Jacot-Guillarmod, M., Pasquier, J., Greub, G., Bongiovanni, M., Achtari, C., & Sahli, R. (2017). Impact of HPV vaccination with Gardasil® in Switzerland. BMC Infectious Diseases, 17(1). https://doi.org/10.1186/s12879-017-2867-x
• Kjær, S. K., Breugelmans, G., Munk, C., Junge, J., Watson, M., & Iftner, T. (2008). Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark. International Journal of Cancer, 123(8). https://doi.org/10.1002/ijc.23712
• Lefèvre, H., Schrimpf, C., Moro, M. R., & Lachal, J. (2018). HPV vaccination rate in French adolescent girls: An example of vaccine distrust. Archives of Disease in Childhood, 103(8). https://doi.org/10.1136/archdischild-2017-313887
• Lynge, E., Thamsborg, L., Larsen, L. G., Christensen, J., Johansen, T., Hariri, J., Christiansen, S., Rygaard, C., & Andersen, B. (2020). Prevalence of high-risk human papillomavirus after HPV-vaccination in Denmark. International Journal of Cancer, 147(12). https://doi.org/10.1002/ijc.33157
• Markowitz, L. E., Liu, G., Hariri, S., Steinau, M., Dunne, E. F., & Unger, E. R. (2016). Prevalence of HPV after introduction of the vaccination program in the United States. Pediatrics, 137(3). https://doi.org/10.1542/peds.2015-1968
• Marlow, L. A.V. (2011). HPV vaccination among ethnic minorities in the UK: Knowledge, acceptability and attitudes. British Journal of Cancer, 105(4). https://doi.org/10.1038/bjc.2011.272
• Marlow, Laura A.V., Zimet, G. D., McCaffery, K. J., Ostini, R., & Waller, J. (2013). Knowledge of human papillomavirus (HPV) and HPV vaccination: An international comparison. Vaccine, 31(5). https://doi.org/10.1016/j.vaccine.2012.11.083
• Mphuru, A., Li, A. J., Kyesi, F., Mwengee, W., Mazige, F., Nshunju, R., Shayo, B., Giattas, M. R., Loharikar, A., & Lyimo, D. (2022). National introduction of human papillomavirus (HPV) vaccine in Tanzania: Programmatic decision-making and implementation. Vaccine, 40. https://doi.org/10.1016/j.vaccine.2021.04.025
• Muñoz, N., Bosch, F. X., de Sanjosé, S., Herrero, R., Castellsagué, X., Shah, K. V., Snijders, P. J. F., & Meijer, C. J. L. M. (2003). Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer. New England Journal of Medicine, 348(6). https://doi.org/10.1056/nejmoa021641
• Osmani, V., & Klug, S. J. (2021). HPV vaccination and the prevention of genital warts and precancerous lesions—current evidence and evaluation. In Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz (Vol. 64, Issue 5). https://doi.org/10.1007/s00103-021-03316-x
• Patel, C., Brotherton, J. M. L., Pillsbury, A., Jayasinghe, S., Donovan, B., Macartney, K., & Marshall, H. (2018). The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: What additional disease burden will a nonavalent vaccine prevent? In Eurosurveillance (Vol. 23, Issue 41). https://doi.org/10.2807/1560-7917.ES.2018.23.41.1700737
• Paul, K. T. (2016). “Saving lives”: Adapting and adopting Human Papilloma Virus (HPV) vaccination in Austria. Social Science and Medicine, 153. https://doi.org/10.1016/j.socscimed.2016.02.006
• Petca, A., Borislavschi, A., Zvanca, M., Petca, R.-C., Sandru, F., & Dumitrascu, M. (2020). Non-sexual HPV transmission and role of vaccination for a better future (Review). Experimental and Therapeutic Medicine, 20(6). https://doi.org/10.3892/etm.2020.9316
• Petrosky, E., Bocchini, J. A., Hariri, S., Chesson, H., Curtis, C. R., Saraiya, M., Unger, E. R., Markowitz, L. E., & Centers for Disease Control and Prevention (CDC). (2015). Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR. Morbidity and Mortality Weekly Report, 64(11), 300–304.
• Pista, A., de Oliveira, C. F., Lopes, C., Cunha, M. J., Tavares, A., Dias, M., Rocha, E., da Conceição Telhado, M., Afonso, A., Loureiro, M., Horgan, C., Marques, I., Cortes, E., Alegra, S., do Carmo Serra, M., Lima, J., Afonso, E., Ladeira, A. P., Gonçalves, L., … Santos, S. (2017). Potential impact of nonavalent HPV vaccine in the prevention of high-grade cervical lesions and cervical cancer in Portugal. International Journal of Gynecology and Obstetrics, 139(1). https://doi.org/10.1002/ijgo.12243
• Riesen, M., Garcia, V., Low, N., & Althaus, C. L. (2017). Modeling the consequences of regional heterogeneity in human papillomavirus (HPV) vaccination uptake on transmission in Switzerland. Vaccine, 35(52). https://doi.org/10.1016/j.vaccine.2017.10.103
• Riesen, M., Konstantinoudis, G., Lang, P., Low, N., Hatz, C., Maeusezahl, M., Spaar, A., Bühlmann, M., Spycher, B. D., & Althaus, C. L. (2018). Exploring variation in human papillomavirus vaccination uptake in Switzerland: A multilevel spatial analysis of a national vaccination coverage survey. In BMJ Open (Vol. 8, Issue 5). https://doi.org/10.1136/bmjopen-2017-021006
• Rondy, M., van Lier, A., van de Kassteele, J., Rust, L., & de Melker, H. (2010). Determinants for HPV vaccine uptake in the Netherlands: A multilevel study. Vaccine, 28(9). https://doi.org/10.1016/j.vaccine.2009.12.042
• Sargazi, N., Takian, A., Yaseri, M., Daroudi, R., Ghanbari Motlagh, A., Nahvijou, A., & Zendehdel, K. (2021). Mothers’ preferences and willingness-to-pay for human papillomavirus vaccines in Iran: A discrete choice experiment study. Preventive Medicine Reports, 23. https://doi.org/10.1016/j.pmedr.2021.101438
• Schülein, S., Taylor, K. J., König, J., Claus, M., Blettner, M., & Klug, S. J. (2016). Factors influencing uptake of HPV vaccination among girls in Germany. BMC Public Health, 16(1). https://doi.org/10.1186/s12889-016-3663-z
• Shahbari, N. A. E., Gesser-Edelsburg, A., Davidovitch, N., Brammli-Greenberg, S., Grifat, R., & Mesch, G. S. (2021). Factors associated with seasonal influenza and HPV vaccination uptake among different ethnic groups in Arab and Jewish society in Israel. International Journal for Equity in Health, 20(1). https://doi.org/10.1186/s12939-021-01523-1
• Shahbari, N. A. E., Gesser-Edelsburg, A., & Mesch, G. S. (2019). Case of paradoxical cultural sensitivity: Mixed method study of web-based health informational materials about the human papillomavirus vaccine in Israel. Journal of Medical Internet Research, 21(5). https://doi.org/10.2196/13373
• Shaltout, M. F., Sallam, H. N., AbouSeeda, M., Moiety, F., Hemeda, H., Ibrahim, A., Sherbini, M. E. L., Rady, H., Gopala, K., & DeAntonio, R. (2014). Prevalence and type distribution of human papillomavirus among women older than 18 years in Egypt: A multicenter, observational study. International Journal of Infectious Diseases, 29. https://doi.org/10.1016/j.ijid.2014.07.029
• Shapiro, G. K., Guichon, J., & Kelaher, M. (2017). Canadian school-based HPV vaccine programs and policy considerations. Vaccine, 35(42). https://doi.org/10.1016/j.vaccine.2017.07.079
• Sharma, S., Deep, A., & Sharma, A. K. (2020). Current Treatment for Cervical Cancer: An Update. Anti-Cancer Agents in Medicinal Chemistry, 20(15). https://doi.org/10.2174/1871520620666200224093301
• Simoens, C., Sabbe, M., Van Damme, P., Beutels, P., & Arbyn, M. (2009). Introduction of human papillomavirus (HPV) vaccination in Belgium, 2007-2008. Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin, 14(46). https://doi.org/10.2807/ese.14.46.19407-en
• Stanley, M. (2014). HPV vaccination in boys and men. Human Vaccines & Immunotherapeutics, 10(7). https://doi.org/10.4161/hv.29137
• Tabrizi, S. N., Brotherton, J. M. L., Kaldor, J. M., Skinner, S. R., Cummins, E., Liu, B., Bateson, D., McNamee, K., Garefalakis, M., & Garland, S. M. (2012). Fall in human papillomavirus prevalence following a national vaccination program. Journal of Infectious Diseases, 206(11). https://doi.org/10.1093/infdis/jis590
• Tanaka, Y., Ueda, Y., Egawa-Takata, T., Yagi, A., Yoshino, K., & Kimura, T. (2016). Outcomes for girls without HPV vaccination in Japan. In The Lancet Oncology (Vol. 17, Issue 7). https://doi.org/10.1016/S1470-2045(16)00147-9
• Tay, S. K., Lee, B. W., Sohn, W. Y., Lee, I. H., Mathur, G., Sanicas, M., & Van Kriekinge, G. (2018). Cost-effectiveness of two-dose human papillomavirus vaccination in Singapore. Singapore Medical Journal, 59(7). https://doi.org/10.11622/smedj.2017085
• The Catalan Institute of Oncology & International Agency for Research on Cancer. (2023). HPV Information Centre. https://hpvcentre.net
• Thinn, M. M., Aung, S., Aung, A., & Tun, N. M. (2023). Current Status of Cervical Cancer Prevention and Screening in Myanmar. In South Asian Journal of Cancer (Vol. 12, Issue 1). https://doi.org/10.1055/s-0043-1764212
• Trétarre, B., Dantony, E., Coureau, G., Defossez, G., Guizard, A. V., Delafosse, P., Daubisse, L., Velten, M., Karima Hammas, Barra, S., Lapotre, B., Plouvier, S., d’Almeida, T., Molinié, F., & Woronoff, A. S. (2023). Trends in incidence of invasive vaginal cancer in France from 1990 to 2018 and survival of recently diagnosed women – A population-based study. European Journal of Obstetrics and Gynecology and Reproductive Biology, 283. https://doi.org/10.1016/j.ejogrb.2023.02.003
• Walwyn, L., Janusz, C. B., Clark, A. D., Prieto, E., Waight, E., & Largaespada, N. (2015). Cost-effectiveness of HPV vaccination in Belize. Vaccine, 33(S1). https://doi.org/10.1016/j.vaccine.2014.12.042
• World Health Organization. (2022). Cervical cancer: Prevention and control. https://www.who.int/news‑room/fact‑sheets/detail/cervical‑cancer
• World Health Organization. (2024). Human papillomavirus (HPV) vaccination coverage. https://www.who.int/news-room/fact- sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer
• Yaghoubi, M., Nojomi, M., Vaezi, A., Erfani, V., Mahmoudi, S., Ezoji, K., Zahraei, S. M., Chaudhri, I., & Moradi-Lakeh, M. (2018). Cost-Effectiveness Analysis of the Introduction of HPV Vaccination of 9-Year-Old-Girls in Iran. Value in Health Regional Issues, 15. https://doi.org/10.1016/j.vhri.2018.03.001
• Zhu, Y., Wu, C. F., Giuliano, A. R., Fernandez, M. E., Ortiz, A. P., Cazaban, C. G., Li, R., Deshmukh, A. A., & Sonawane, K. (2022). Tdap-HPV vaccination bundling in the USA: Trends, predictors, and implications for vaccine series completion. Preventive Medicine, 164. https://doi.org/10.1016/j.ypmed.2022.107218
• Zhuang, Q. Y., Wong, R. X., Chen, W. M. D., & Guo, X. X. (2016). Knowledge, attitudes and practices regarding human papillomavirus vaccination among young women attending a tertiary institution in Singapore. Singapore Medical Journal, 57(6). https://doi.org/10.11622/smedj.2016108